Researchers have conducted a retrospective study of over 3100 people with chronic kidney disease to evaluate the association between mineralocorticoid receptor antagonist (MRA) use and renal outcomes. The analysis revealed an association between MRA use and a reduced risk for the initiation of renal replacement therapy across multiple subgroups of patients with chronic kidney disease. These findings reinforce the use of MRAs in treatment plans for various groups of people with chronic kidney disease who are not undergoing dialysis.
